Loading…
Kilitch Drugs (India) (KILITCH)₹200.54+4.94%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Kilitch Drugs (India) reported sales of ₹44.87 Cr, up 4.0% from Jun 2025, and net profit of ₹1.97 Cr, down 13.6% year on year. For the year to Mar 2026, sales were ₹235 Cr and net profit ₹30.12 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 41.18 | 31.76 | 44.79 | 33.42 | 47.49 | 56.12 | 61.27 | 43.13 | 48.90 | 53.83 | 89.63 | 44.87 |
| Expenses | 32.51 | 29.44 | 37.68 | 31.72 | 41.33 | 47.39 | 46.53 | 39.82 | 43.81 | 47.60 | 67.37 | 41.88 |
| Operating Profit | 8.61 | 2.29 | 7.09 | 1.67 | 6.09 | 8.74 | 14.58 | 3.27 | 5.05 | 6.16 | 22.15 | 2.95 |
| OPM % | 20.9% | 7.2% | 15.8% | 5.0% | 12.8% | 15.5% | 23.8% | 7.5% | 10.3% | 11.4% | 24.7% | 6.5% |
| Other Income | 0.50 | 2.97 | 0.48 | 2.58 | 5.17 | 1.74 | 1.71 | 2.57 | 6.67 | 1.54 | 0.50 | 2.91 |
| Interest | 1.50 | 1.59 | 1.31 | 1.72 | 0.30 | 1.39 | 1.59 | 1.52 | 1.43 | 1.14 | 1.43 | 0.87 |
| Depreciation | 0.81 | 0.80 | 0.92 | 0.84 | 0.60 | 0.80 | 0.84 | 0.83 | 0.85 | 0.93 | 0.97 | 1.08 |
| Profit before tax | 6.79 | 2.84 | 5.31 | 1.66 | 10.35 | 8.26 | 13.85 | 3.46 | 9.41 | 5.60 | 20.24 | 3.88 |
| Tax % | 25.0% | 38.2% | 30.6% | 93.4% | 16.8% | 32.0% | 26.2% | 34.5% | 14.5% | 23.0% | 26.4% | 48.9% |
| Net Profit | 5.11 | 1.75 | 3.69 | 0.12 | 8.64 | 5.63 | 10.25 | 2.28 | 8.06 | 4.33 | 14.94 | 1.97 |
| EPS (Rs) | 1.36 | 0.84 | 1.04 | 0.39 | 2.47 | 1.71 | 2.98 | 0.88 | 2.35 | 1.28 | 4.17 | 0.84 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 20.99 | 26.99 | 51.03 | 81.99 | 52.99 | 67.99 | 114 | 140 | 154 | 198 | 235 | 237 |
| Expenses | 24.96 | 27.96 | 44.94 | 74.93 | 52.93 | 62.87 | 104 | 122 | 130 | 167 | 198 | 201 |
| Operating Profit | −4.01 | −1.01 | 6.01 | 7.01 | 0.00 | 5.01 | 10.01 | 17.99 | 24.01 | 31.99 | 37.01 | 36.31 |
| OPM % | −19.0% | −2.0% | 11.0% | 9.0% | 0.8% | 8.0% | 9.0% | 13.0% | 16.0% | 16.0% | 16.0% | 15.3% |
| Other Income | 2.01 | 1.01 | 3.01 | 4.01 | 4.01 | 3.01 | 3.01 | 3.01 | 4.01 | 11.02 | 11.02 | 11.62 |
| Interest | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | 0.99 | 0.99 | 4.99 | 5.98 | 4.99 | 5.99 | 4.87 |
| Depreciation | 9.99 | 9.99 | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 | 3.99 | 2.99 | 2.99 | 3.99 | 3.83 |
| Profit before tax | −12.02 | −9.01 | 6.01 | 9.01 | 2.01 | 5.01 | 10.02 | 12.01 | 19.03 | 34.04 | 39.06 | 39.13 |
| Tax % | −4.0% | −5.0% | 16.1% | 55.0% | 48.0% | 27.0% | 35.0% | 31.0% | 30.0% | 28.0% | 24.1% | — |
| Exceptional items | −0.41 | 0.06 | 0.91 | 1.03 | 1.06 | 0.82 | 0.86 | 0.65 | 0.94 | 5.10 | 4.67 | — |
| Net Profit | −11.04 | −9.04 | 5.02 | 4.01 | 1.01 | 4.01 | 6.03 | 8.02 | 14.04 | 25.07 | 30.12 | 29.30 |
| EPS (Rs) | −3.91 | −3.10 | 1.73 | 1.16 | 0.26 | 1.10 | 2.18 | 3.09 | 4.19 | 7.66 | 8.66 | 8.64 |
| Dividend payout % | 0.0% | 0.0% | 13.0% | 20.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13.01 | 13.02 | 13.03 | 14.03 | 15.03 | 15.05 | 15.04 | 16.05 | 16.05 | 16.06 | 16.04 | 35.11 |
| Reserves | 107 | 94.87 | 87.89 | 97.92 | 106 | 103 | 112 | 124 | 136 | 160 | 186 | 245 |
| Borrowings | 0.00 | 0.00 | 1.01 | 0.99 | 8.99 | 12.99 | 15.01 | 19.99 | 21.98 | 32.02 | 48.99 | 89.01 |
| Other Liabilities | 6.97 | 7.96 | 10.95 | 14.93 | 12.93 | 12.00 | 61.05 | 49.97 | 45.96 | 31.88 | 61.21 | 89.23 |
| Total Liabilities | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 458 |
| Fixed Assets | 9.01 | 42.01 | 33.02 | 32.98 | 32.01 | 32.02 | 30.01 | 64.99 | 64.01 | 62.01 | 64.03 | 67.02 |
| CWIP | 0.00 | 0.00 | 1.01 | 3.01 | 20.02 | 30.03 | 65.14 | 3.01 | 4.01 | 6.01 | 47.04 | 140 |
| Investments | 71.72 | 48.81 | 52.80 | 55.84 | 52.82 | 51.86 | 59.77 | 70.72 | 61.81 | 71.73 | 71.79 | 74.73 |
| Other Assets | 46.05 | 25.03 | 26.05 | 35.04 | 38.05 | 30.04 | 47.08 | 71.15 | 90.17 | 100 | 129 | 176 |
| Inventories | 2.01 | 3.01 | 3.01 | 3.01 | 5.01 | 6.01 | 4.01 | 5.01 | 2.01 | 4.01 | 15.02 | 12.01 |
| Trade receivables | 13.01 | 16.02 | 15.03 | 21.02 | 19.02 | 16.04 | 23.02 | 41.09 | 54.09 | 63.11 | 85.15 | 120 |
| Cash & equivalents | 5.01 | 3.01 | 2.01 | 5.02 | 8.02 | 3.01 | 12.03 | 10.02 | 20.06 | 20.04 | 10.03 | 17.05 |
| Total Assets | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 458 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −8.01 | 17.03 | 1.01 | 1.01 | 0.00 | 4.01 | 46.06 | 6.01 | 3.01 | −2.01 | 18.01 | 24.03 |
| Cash from investing activity | −30.93 | −19.97 | −1.99 | −3.99 | −13.97 | −9.99 | −37.94 | −14.99 | 7.99 | −7.99 | −39.97 | −99.79 |
| Cash from financing activity | 0.00 | 0.00 | 0.00 | 6.02 | 17.07 | 1.01 | 2.01 | 7.02 | −1.01 | 9.03 | 13.05 | 82.25 |
| Net cash flow | −38.86 | −1.99 | 0.00 | 1.99 | 2.99 | −4.98 | 9.97 | −1.99 | 9.96 | −0.99 | −8.97 | 5.98 |
| Capex | 1.99 | 42.84 | 0.99 | 2.99 | 18.95 | 9.97 | 35.89 | 7.97 | 3.98 | 5.98 | 46.84 | 99.74 |
| Free cash flow | −10.03 | −26.09 | 0.00 | −2.01 | −19.06 | −6.02 | 9.03 | −2.01 | −1.01 | −8.03 | −29.11 | −76.21 |
| CFO / OP % | 430.0% | −442.1% | −202.0% | 24.9% | 60.0% | 1,598.0% | 877.0% | 79.0% | 38.9% | 23.0% | 82.0% | 91.9% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 243 | 286 | 196 | 148 | 86 | 109 | 122 | 132 | 142 | 149 | 156 | 186 |
| Inventory days | 123 | 109 | 83 | 38 | 35 | 69 | 34 | 27 | 9 | 17 | 52 | 32 |
| Days payable | 124 | 154 | 184 | 108 | 33 | 89 | 525 | 239 | 200 | 118 | 189 | 230 |
| Cash conversion cycle | 244 | 242 | 97 | 80 | 90 | 90 | −366 | −78 | −47 | 51 | 21 | −10 |
| Working capital days | 196 | 233 | 114 | 92 | 36 | 21 | −224 | −41 | −5 | 29 | 55 | 48 |
| ROCE % | — | −9.9% | −9.0% | 5.0% | 6.0% | 1.0% | 3.0% | 6.0% | 10.0% | 13.1% | 16.0% | 13.1% |
For the Jun 2026 quarter, Kilitch Drugs (India) reported sales of ₹44.87 Cr, up 4.0% year on year and net profit of ₹1.97 Cr, down 13.6% year on year. The operating margin was 6.5%.
Kilitch Drugs (India)'s sales for the year to Mar 2026 were ₹235 Cr; over the last twelve months they were ₹237 Cr.
Net profit for the year to Mar 2026 was ₹30.12 Cr, and ₹29.30 Cr over the last twelve months. Earnings per share over the same trailing period were ₹8.64.
Kilitch Drugs (India) reported borrowings of ₹89.01 Cr at Mar 2026, against cash and equivalents of ₹17.05 Cr.
Cash from operations was ₹24.03 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹76.21 Cr.